Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Publication|Articles|July 16, 2025
Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic
Author(s)Ashling Wahner
Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.
Advertisement
Advertisement
As the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting drew to a close, top experts across oncology fields reflected on the data that signaled future developments regarding novel biomarker testing strategies, increasingly personalized modifications of standard chemotherapy regimens, and optimal use of PD-1/PD-L1 inhibition.
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
FDA has granted RMAT and fast track designations to celma-cel as a frontline consolidation in large B-cell lymphoma.
The CD70-targeting CAR T cell therapy, ALLO-316, demonstrated encouraging results in previously treated patients with advanced ccRCC.
Advertisement
Advertisement